A nonpeptidic, selective, brain-penetrant agonist of nociceptin/orphanin FQ receptor (NOP receptor/ORL1) with pKi of 9.41.

A non-peptide, selective RGS4 inhibitor that inhibits RGS4/Gα(o) binding with 3 to 5 uM potency.

A nonpeptide, cell-permeable STAT3 inhibitor that binds directly to the pTyr705 binding site of the STAT3 monomer.

A nonnucleoside, competitive, small-molecule inhibitor of human ribonucleotide reductase (hRR) that binds to the large subunit hRRM1 at the catalytic site (C-site) with Kd of 37.4 uM, IC50 of 32 uM.

A non-immunosuppressive FTY720 analogue, PKCδ activator with higher antiproliferative potency with IC50 of 2.4, 2.4, and 3.5 uM in Huh7, Hep3B, and PLC5 cells, respectively.

A noncovalent small molecule binder to Keap1 (Kd=6 uM) and selective activator of Nrf2 signaling.

A newly identified, small molecule HuR inhibitor that disrupts HuR multimerization modules and reduces tumor cell survival and proliferation..

A new compound which is similar with +JQ-1，BET bromodomain inhibitor

A new broad spectrum industrial microbicide with applications in material and coating preservation. .

A negative control of VU-WS113, which is a potent inhibitor of Wnt signaling with EC50 of 80 nM that selectively potentiates CK1α kinase activity..

A negative allosteric modulator of the Frizzled4 (Fzd4) receptor and a Wnt/β-catenin pathway inhibitor with pEC50 value of 5.74 for inhibition of Wnt antagonism.

A naturally occurring tetranortriterpenoid that has been found to act as a potent, selective, small-molecule agonist of TrkB with Kd of 1.4 uM.

A naturally occurring nucleoside analog that possesses antitumor activity, also is a potent and efficacious readthrough agent.

A natural tetranortriterpenoid compound that inhibits Hsp90 and induce the degradation of Hsp90-dependent client proteins.

A natural poduct that functions as a splicing inhibitor with IC50 of 35 uM, blocks a late stage of spliceosome assembly..

A natural furanocoumarin that is found to be a potent inhibitor of debenzylation activity of CYP3A4 enzyme with IC50 of 24.92 uM.

A nanomolar potent, selective, and orally bioavailable glycine transporter type-1 (GlyT1) inhibitor for the treatment of negative symptoms associated with schizophrenia.

A mycotoxin produced from F. moniliforme, and an inhibitor of ceramide synthase (sphingosine N-acyltransferase/CerS).

A multichannel blocker agent that has antiarrhythmic activity.

A moderately potent, but highly selective α2-adrenoceptor antagonist, the only reported selective antagonist at the α2B-adrenoceptor not having potent α1-adrenoceptor antagonist activity.

A metabolite of tamoxifen, orally active non-steroidal selective estrogen receptor modulator (SERM) for the treatment of estrogen receptor-positive breast cancer..

A metabolite of ST1535, which is potent, selective A2A adenosine receptor antagonist with Ki of 6.6 nM..

A metabolite of Gefitinib, which is a potent inhibitor of tyrosine phosporylation in EGFR..

A membrane permeable IP3 receptor antagonist and broad TRP channels (TRPC5, TRPM2) blcoker.

A melanoma-selective anticancer agent (IC50=30 nM, Malme-3M cell line), induces cell death by autophagocytosis, targeting the cancer-protective protein dermcidin.

A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively.

A Mannich base compound, selective and orally active JAK3 inhibitor that blocks IL-2-induced activation of JAK3 and downstream substrates STAT5a/b.

A macrolide antibiotic that effectively inhibits tumor angiogenesis by suppressing VEGFR2-mediated signaling pathways in lung cancer.

A loop diuretic used to treat high blood pressure and the swelling, a novel ligand and inhibitor of MAP2K6 kinase that inhibits MAP2K6 in part through alkylation of a nonconserved cysteine residue.

A long acting beta-adrenoceptor agonist (LABA) used in the treatment of asthma.